MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent - PubMed (original) (raw)
. 2008 Oct;111(3):497-504.
doi: 10.1007/s10549-007-9797-z. Epub 2007 Nov 18.
Affiliations
- PMID: 18026875
- DOI: 10.1007/s10549-007-9797-z
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent
Ronit I Yarden et al. Breast Cancer Res Treat. 2008 Oct.
Abstract
A functional single nucleotide polymorphism in the promoter of the MDM2 gene, SNP309 (T>G), was recently found to accelerate tumorigenesis in early onset cancer cases. The SNP309 G-allele, introduces an SP1 site in the MDM2 promoter, resulting in enhanced MDM2 expression and activity. Thus, the G-allele of MDM2 SNP309 may represent a cancer predisposing allele. In this report, we assessed the role of SNP309 as a modifier of mutant BRCA1/BRCA2 alleles in inherited breast and ovarian cancer cases among Ashkenazi-Jewish (AJ) women. We genotyped several subsets of AJ women: 138 healthy women, 140 affected BRCA1/2 mutation carriers, 120 asymptomatic BRCA1/2 mutation carriers and 187 sporadic breast cancer patients. The frequency of GG genotype of SNP309 was similar among the different groups. Interestingly, we found almost three times higher frequency of the GG genotype among BRCA1/2 carriers diagnosed with breast and/or ovarian cancer at or under the age of 51 years compared with carriers diagnosed with cancer above the age of 51 years (allele frequency, P = 0.019). The GG genotype was significantly associated with breast and ovarian cancer risk among BRCA1/2 carriers diagnosed before 51 years of age (OR, 3.93; 95% CI, 1.41-10.90, P = 0.009). No significant difference in frequency of the GG genotype was observed between early and late onset non-carrier cancer patients and no association with risk, OR, 1.30; 95% CI 0.69-2.47, P = 0.419). These data suggest that MDM2 SNP309 acts as a modifier of mutant BRCA1/2 mutant alleles in AJ and may accelerate breast and ovarian carcinogenesis in genetically predisposed individuals.
Similar articles
- MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M. Wasielewski M, et al. Breast Cancer Res Treat. 2007 Aug;104(2):153-7. doi: 10.1007/s10549-006-9407-5. Epub 2006 Nov 2. Breast Cancer Res Treat. 2007. PMID: 17080308 - Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.
Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T. Nechushtan H, et al. BMC Cancer. 2009 Feb 18;9:60. doi: 10.1186/1471-2407-9-60. BMC Cancer. 2009. PMID: 19226467 Free PMC article. - Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Satagopan JM, et al. Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589 - Hereditary ovarian cancer in Ashkenazi Jews.
Robles-Díaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Robles-Díaz L, et al. Fam Cancer. 2004;3(3-4):259-64. doi: 10.1007/s10689-004-9552-0. Fam Cancer. 2004. PMID: 15516850 Review. - Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Friebel TM, Domchek SM, Rebbeck TR. Friebel TM, et al. J Natl Cancer Inst. 2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091. J Natl Cancer Inst. 2014. PMID: 24824314 Free PMC article. Review.
Cited by
- A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
Jalilvand A, Yari K, Aznab M, Rahimi Z, Salahshouri Far I, Mohammadi P. Jalilvand A, et al. J Clin Lab Anal. 2020 Dec;34(12):e23529. doi: 10.1002/jcla.23529. Epub 2020 Sep 20. J Clin Lab Anal. 2020. PMID: 32951271 Free PMC article. - Investigation of metastasis-associated in colon cancer-1 genetic variants in the development and clinicopathologcial characteristics of uterine cervical cancer in Taiwanese women.
Sun YH, Chou YH, Ou CC, Ng SC, Shen HP, Lee YC, Hsu CF, Yang SF, Wang PH. Sun YH, et al. Int J Med Sci. 2020 Feb 4;17(4):490-497. doi: 10.7150/ijms.40204. eCollection 2020. Int J Med Sci. 2020. PMID: 32174779 Free PMC article. - Impact of the Receptor for Advanced Glycation End Products Genetic Polymorphisms on the Progression in Uterine Cervical Cancer.
Lee CY, Ng SC, Hsiao YH, Yang SF, Hsu CF, Wang PH. Lee CY, et al. J Cancer. 2018 Oct 10;9(21):3886-3893. doi: 10.7150/jca.27960. eCollection 2018. J Cancer. 2018. PMID: 30410591 Free PMC article. - Relationship of genetic variant distributions of WW domain-containing oxidoreductase gene with uterine cervical cancer.
Lin YH, Hsiao YH, Wu WJ, Yang SF, Hsu CF, Kang YT, Wang PH. Lin YH, et al. Int J Med Sci. 2018 Jun 14;15(10):1005-1013. doi: 10.7150/ijms.25553. eCollection 2018. Int J Med Sci. 2018. PMID: 30013442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous